Anastrozole

CLINICAL USE

Treatment of breast cancer in post- menopausal women

DOSE IN NORMAL RENAL FUNCTION

1 mg daily

PHARMACOKINETICS

Molecular weight : 293.4

%Protein binding : 40

%Excreted unchanged in urine :

<10 :

Volume of distribution (L/kg) : No data

half-life – normal/ESRD (hrs) : 40–50/Probably unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Dialysed. Dose as in normal renal function

HD : Dialysed. Dose as in normal renal function

HDF/high flux : Dialysed. Dose as in normal renal function

CAV/VVHD : Dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Oestrogen-containing therapies: avoid concomitant administration as would negate pharmacological action

amoxifen: avoid concomitant administration

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Anastrozole is extensively metabolised in the liver; only 10% of unchanged drug and 60% of metabolites (largely inactive) are excreted in the urine

Although renal clearance of anastrozole decreases proportionally with creatinine clearance, the reduction in renal clearance does not affect total body clearance of anastrozole. According to the American SPC a dose reduction is not required in renal impairment

In the UK, the SPC recommends avoiding the use of anastrozole in patients with GFR<20 mL/min

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home